{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:15:37Z","timestamp":1791062137286,"version":"4.1.0"},"reference-count":163,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T00:00:00Z","timestamp":1327968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anemia of chronic disease (ACD) or anemia of inflammation is prevalent in patients with chronic infection, autoimmune disease, cancer, and chronic kidney disease. ACD is associated with poor prognosis and lower quality of life. Management of ACD using intravenous iron and erythropoiesis stimulating agents are ineffective for some patients and are not without adverse effects, driving the need for new alternative therapies. Recent advances in our understanding of the molecular mechanisms of iron regulation reveal that increased hepcidin, the iron regulatory hormone, is a key factor in the development of ACD. In this review, we will summarize the role of hepcidin in iron homeostasis, its contribution to the pathophysiology of ACD, and novel strategies that modulate hepcidin and its target ferroportin for the treatment of ACD. Am. J. Hematol. 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23110","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T06:19:25Z","timestamp":1325139565000},"page":"392-400","source":"Crossref","is-referenced-by-count":148,"title":["Targeting the hepcidin\u2013ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation"],"prefix":"10.1002","volume":"87","author":[{"given":"Chia Chi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie L.","family":"Babitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,31]]},"reference":[{"key":"e_1_2_16_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041809"},{"key":"e_1_2_16_3_2","first-page":"235","article-title":"The anemia of chronic disorders","volume":"3","author":"Cartwright GE","year":"1966","journal-title":"Semin Hematol"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI100432"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21441"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0672"},{"key":"e_1_2_16_7_2","first-page":"1043","article-title":"The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease","volume":"41","author":"Ganz T","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420945"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051755"},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104742"},{"key":"e_1_2_16_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2009.06.001"},{"key":"e_1_2_16_12_2","doi-asserted-by":"crossref","first-page":"3171S","DOI":"10.1093\/jn\/134.11.3171S","article-title":"Iron, free radicals, and oxidative injury","volume":"134","author":"McCord JM","year":"2004","journal-title":"J Nutr"},{"key":"e_1_2_16_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.06.009"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198206243062504"},{"key":"e_1_2_16_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-258467"},{"key":"e_1_2_16_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014399"},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E07-01-0060"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1629"},{"key":"e_1_2_16_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195503"},{"key":"e_1_2_16_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215686"},{"key":"e_1_2_16_21_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.1.5145"},{"key":"e_1_2_16_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.028"},{"key":"e_1_2_16_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathol.4.110807.092205"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI101690"},{"key":"e_1_2_16_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-29916-5_7"},{"key":"e_1_2_16_26_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.012809.104804"},{"key":"e_1_2_16_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195651"},{"key":"e_1_2_16_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.072632499"},{"key":"e_1_2_16_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3375"},{"key":"e_1_2_16_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1260"},{"key":"e_1_2_16_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0896-399"},{"key":"e_1_2_16_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/75534"},{"key":"e_1_2_16_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1274"},{"key":"e_1_2_16_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1053"},{"key":"e_1_2_16_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2009.01.010"},{"key":"e_1_2_16_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277954"},{"key":"e_1_2_16_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.11.016"},{"key":"e_1_2_16_38_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.013"},{"key":"e_1_2_16_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.335"},{"key":"e_1_2_16_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1777"},{"key":"e_1_2_16_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.320"},{"key":"e_1_2_16_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2009.10.008"},{"key":"e_1_2_16_43_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31342"},{"key":"e_1_2_16_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160184"},{"key":"e_1_2_16_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06728.x"},{"key":"e_1_2_16_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2007.06.014"},{"key":"e_1_2_16_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.10.010"},{"key":"e_1_2_16_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111567"},{"key":"e_1_2_16_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339952"},{"key":"e_1_2_16_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-139915"},{"key":"e_1_2_16_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1159"},{"key":"e_1_2_16_52_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409808102"},{"key":"e_1_2_16_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0159-y"},{"key":"e_1_2_16_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027631"},{"key":"e_1_2_16_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-008-0313-7"},{"key":"e_1_2_16_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033969"},{"key":"e_1_2_16_57_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.049"},{"key":"e_1_2_16_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173641"},{"key":"e_1_2_16_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2007.54"},{"key":"e_1_2_16_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3932(91)90092-M"},{"key":"e_1_2_16_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj038"},{"key":"e_1_2_16_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.070"},{"key":"e_1_2_16_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1520"},{"key":"e_1_2_16_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000018409.45834.FA"},{"key":"e_1_2_16_65_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1681\/ASN.V112335","article-title":"Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients","volume":"11","author":"Moreno F","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_16_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"e_1_2_16_67_2","first-page":"1467","article-title":"Anemia of chronic disease in patients with rheumatoid arthritis: Aspects of prevalence, outcome, diagnosis, and the effect of treatment on disease activity","volume":"33","author":"Swaak A","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_16_68_2","unstructured":"FDA. Drugs@FDA: Epogen\/Procrit FDA. Application #: (BLA) 103234;1989. Available from:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index. cfm?fuseaction=Search.DrugDetails.Accessed on 3 November 2011."},{"key":"e_1_2_16_69_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.09.019"},{"key":"e_1_2_16_70_2","unstructured":"FDA. FDA Drug Safety Communication: Erythropoiesis\u2010Stimulating Agents (ESAs): Procrit Epogen and Aranesp; 2\/26\/2010. Available from:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsand Providers\/ucm200297.htm. Accessed on 27 October 2011."},{"key":"e_1_2_16_71_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749309099269"},{"key":"e_1_2_16_72_2","doi-asserted-by":"publisher","DOI":"10.1159\/000092852"},{"key":"e_1_2_16_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200160"},{"key":"e_1_2_16_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.159"},{"key":"e_1_2_16_75_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.12.030"},{"key":"e_1_2_16_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"e_1_2_16_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"e_1_2_16_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60502-X"},{"key":"e_1_2_16_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.8.914"},{"key":"e_1_2_16_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.2885"},{"key":"e_1_2_16_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.150"},{"key":"e_1_2_16_82_2","volume-title":"Injection, for Intravenous or Subcutaneous Use [package insert]","author":"Epogen\u00ae (Epoetin Alfa)","year":"2011"},{"key":"e_1_2_16_83_2","volume-title":"Injection, for Intravenous or Subcutaneous Use [package insert]","author":"Aranesp\u00ae (Darbepoetin Alfa)","year":"2011"},{"key":"e_1_2_16_84_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05931108"},{"key":"e_1_2_16_85_2","doi-asserted-by":"publisher","DOI":"10.1159\/000045053"},{"key":"e_1_2_16_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.487"},{"key":"e_1_2_16_87_2","first-page":"34","article-title":"An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin","volume":"48","author":"Markowitz GS","year":"1997","journal-title":"Clin Nephrol"},{"key":"e_1_2_16_88_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006091034"},{"key":"e_1_2_16_89_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-2-231"},{"key":"e_1_2_16_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404562"},{"key":"e_1_2_16_91_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050606"},{"key":"e_1_2_16_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.3644"},{"key":"e_1_2_16_93_2","doi-asserted-by":"crossref","unstructured":"SteensmaDP SasuBJ SloanJA et al.The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy\u2010associated anemia treated in a controlled trial.J Clin Oncol 29: 2011 (suppl; abstr 9031).","DOI":"10.1200\/jco.2011.29.15_suppl.9031"},{"key":"e_1_2_16_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.21"},{"key":"e_1_2_16_95_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01420406"},{"key":"e_1_2_16_96_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005080804"},{"key":"e_1_2_16_97_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K187"},{"key":"e_1_2_16_98_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2001.06894.x"},{"key":"e_1_2_16_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)67962-2"},{"key":"e_1_2_16_100_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.78a.10156"},{"key":"e_1_2_16_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2763"},{"key":"e_1_2_16_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245977"},{"key":"e_1_2_16_103_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9222-0"},{"key":"e_1_2_16_104_2","volume-title":"Anti\u2010Hepcidin Antibodies and Uses Thereof","author":"Leung DDM","year":"2011"},{"key":"e_1_2_16_105_2","unstructured":"Lily. Clinical Development Pipeline;2011. Available from:http:\/\/www.lilly.com\/SiteCollectionDocuments\/FlashFiles\/PipeLine\/Clinical%20Development%20Pipeline\/13.html. Accessed on 14 October 2011."},{"key":"e_1_2_16_106_2","unstructured":"Alnylam Pharmaceuticals.ALN\u2010HPN: Refractory Anemia;2011. Available from:http:\/\/www.alnylam.com\/Programs\u2010and\u2010Pipeline\/Alnylam\u20105x15\/Refractory\u2010Anemia.php. Accessed on 27 September 2011."},{"key":"e_1_2_16_107_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-010-9210-4"},{"key":"e_1_2_16_108_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33494"},{"key":"e_1_2_16_109_2","unstructured":"Xenon Isis and Xenon Collaborate to Develop Antisense Drugs Against Hemojuvelin and Hepcidin;2010. Available from: http:\/\/www.xenon\u2010pharma. com\/2010\/11\/isis\u2010and\u2010xenon\u2010collaborate\u2010to\u2010develop\u2010antisense\u2010drugs\u2010against\u2010hemojuvelin\u2010and\u2010hepcidin\/. Accessed on 28 September 2011."},{"key":"e_1_2_16_110_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0022-3565(24)37605-0","article-title":"In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration","volume":"286","author":"Graham MJ","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_16_111_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj3180001"},{"key":"e_1_2_16_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(04)03294-5"},{"key":"e_1_2_16_113_2","doi-asserted-by":"crossref","unstructured":"HohlbaumA TrentmannS GilleH et al. Podium #92. Exploiting lipocalin biochemistry for the treatment of anemia: Discovery and characterization of an anti\u2010hepcidin therapeutic. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011) May 22\u201326 2011. Vancouver BC Canada . Am J Hematol 2011;86(9).","DOI":"10.1002\/ajh.22083"},{"key":"e_1_2_16_113_3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21903"},{"key":"e_1_2_16_114_2","unstructured":"Pieris. Preclinical Pipeline PRS\u2010080; 10\/19.2011. Available from:http:\/\/www.pieris\u2010ag.com\/pipeline\/prs\u2010080.php. Accessed on 3 November 2011."},{"key":"e_1_2_16_115_2","first-page":"253","article-title":"Toward third\u2010generation aptamers: Spiegelmers and their therapeutic prospects","volume":"6","author":"Vater A","year":"2003","journal-title":"Curr Opin Drug Discov Devel"},{"key":"e_1_2_16_116_2","first-page":"224","article-title":"Nucleic acid aptamers for target validation and therapeutic applications","volume":"16","author":"Pendergrast PS","year":"2005","journal-title":"J Biomol Tech"},{"key":"e_1_2_16_117_2","unstructured":"Noxxon. NOX\u2010H94;2011. Available from:http:\/\/www.noxxon.com\/index. php?option=com_content&view=article&id=88&Itemid=100. Accessed on 17 October 2011."},{"key":"e_1_2_16_118_2","doi-asserted-by":"crossref","unstructured":"SchwoebelF SellS MaaschC et al. Podium #91. NOX\u2010H94 In vitro and in vivo characterization of a hepcidin blocking spiegelmer. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011) May 22\u201326 2011. Vancouver BC Canada: Am J Hematol 2011;86(9):E47","DOI":"10.1002\/ajh.22083"},{"key":"e_1_2_16_118_3","first-page":"E47","volume":"86","author":"Schwoebel F","year":"2011","journal-title":"Am J Hematol"},{"key":"e_1_2_16_119_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.178533"},{"key":"e_1_2_16_120_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142711"},{"key":"e_1_2_16_121_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070601"},{"key":"e_1_2_16_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e3282f1ab04"},{"key":"e_1_2_16_123_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006121348"},{"key":"e_1_2_16_124_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105547"},{"key":"e_1_2_16_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.10.003"},{"key":"e_1_2_16_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0409-386"},{"key":"e_1_2_16_127_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8"},{"key":"e_1_2_16_128_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI13505"},{"key":"e_1_2_16_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.06.052"},{"key":"e_1_2_16_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1888"},{"key":"e_1_2_16_131_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-345066"},{"key":"e_1_2_16_132_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-313064"},{"key":"e_1_2_16_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2011.06.019"},{"key":"e_1_2_16_134_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.044"},{"key":"e_1_2_16_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003359900391"},{"key":"e_1_2_16_136_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289082"},{"key":"e_1_2_16_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(02)00088-6"},{"key":"e_1_2_16_138_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2006.00279.x"},{"key":"e_1_2_16_139_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/459278"},{"key":"e_1_2_16_140_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1186"},{"key":"e_1_2_16_141_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-271791"},{"key":"e_1_2_16_142_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1075-4"},{"key":"e_1_2_16_143_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377"},{"key":"e_1_2_16_144_2","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","author":"Lang VR","year":"2011","journal-title":"Rheumatology"},{"key":"e_1_2_16_145_2","doi-asserted-by":"crossref","unstructured":"EdwardsCJ.IL\u20106 inhibition and infection: Treating patients with tocilizumab. Rheumatology (2011) doi: 10.1093\/rheumatology\/ker311.","DOI":"10.1093\/rheumatology\/ker311"},{"key":"e_1_2_16_146_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152008785914752"},{"key":"e_1_2_16_147_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107527200"},{"key":"e_1_2_16_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.01.001"},{"key":"e_1_2_16_149_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-009-0588-3"},{"key":"e_1_2_16_150_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12479237"},{"key":"e_1_2_16_151_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198904133201506"},{"key":"e_1_2_16_152_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-309708"},{"key":"e_1_2_16_153_2","doi-asserted-by":"publisher","DOI":"10.1159\/000098645"},{"key":"e_1_2_16_154_2","doi-asserted-by":"publisher","DOI":"10.5301\/JN.2010.1830"},{"key":"e_1_2_16_155_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP74025"},{"key":"e_1_2_16_156_2","first-page":"474A","article-title":"Vitamin D as a new regulator of iron metabolism: Vitamin D suppresses hepcidin in vitro and in vivo","volume":"22","author":"Bacchetta J","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_16_157_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074837"},{"key":"e_1_2_16_158_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00152.x"},{"key":"e_1_2_16_159_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-146134"},{"key":"e_1_2_16_160_2","doi-asserted-by":"crossref","unstructured":"FungE HsuJ DamoiseauxR et al. Poster #198. High throughput screen identifies two classes of small molecules as hepcidin antagonists. In: Fourth Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2011) May 22\u201326 2011. Vancouver BC Canada. Am J Hematol 2011;86(9):E140","DOI":"10.1002\/ajh.22083"},{"key":"e_1_2_16_160_3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22117"},{"key":"e_1_2_16_161_2","volume-title":"Anti\u2010Ferroportin 1 Monoclonal Antibodies and Uses Thereof","author":"Leung DDM","year":"2010"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23110","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:15:19Z","timestamp":1742174119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,31]]},"references-count":163,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/ajh.23110"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23110","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,31]]}}}